{\rtf1\ansi\uc1\deff0\deflang1024
{\fonttbl{\f0\fnil\fcharset0 Times New Roman;}
{\f1\fnil\fcharset0 Arial;}
{\f2\fnil\fcharset0 Arial;}
{\f3\fnil\fcharset0 Courier New;}
{\f4\fnil\fcharset0 Zapf Chancery;}
{\f5\fnil\fcharset0 STIXGeneral;}
{\f6\fnil\fcharset0 MS Gothic;}
}
{\colortbl;
\red0\green0\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red0\green255\blue0;
\red255\green0\blue255;
\red255\green0\blue0;
\red255\green255\blue0;
\red255\green255\blue255;
}
{\stylesheet
{\s0\qj\widctlpar\f0\fs24 \snext0 Normal;}
{\cs10 \additive\ssemihidden Default Paragraph Font;}
{\s1\qc\sb240\sa120\keepn\f0\b\fs40 \sbasedon0\snext0 Part;}
{\s2\ql\sb240\sa120\keepn\f0\b\fs40 \sbasedon0\snext0 heading 1;}
{\s3\ql\sb240\sa120\keepn\f0\b\fs32 \sbasedon0\snext0 heading 2;}
{\s4\ql\sb240\sa120\keepn\f0\b\fs32 \sbasedon0\snext0 heading 3;}
{\s5\ql\sb240\sa120\keepn\f0\b\fs24 \sbasedon0\snext0 heading 4;}
{\s6\ql\sb240\sa120\keepn\f0\b\fs24 \sbasedon0\snext0 heading 5;}
{\s7\ql\sb240\sa120\keepn\f0\b\fs24 \sbasedon0\snext0 heading 6;}
{\s8\qr\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext8 rightpar;}
{\s9\qc\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext9 centerpar;}
{\s10\ql\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext10 leftpar;}
{\s11\ql\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext0 equation;}
{\s12\ql\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext0 equationNum;}
{\s13\ql\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext0 equationAlign;}
{\s14\ql\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext0 equationAlignNum;}
{\s15\ql\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext0 equationArray;}
{\s16\ql\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext0 equationArrayNum;}
{\s17\ql\sb120\sa120\keep\widctlpar\f0\fs20 \sbasedon0\snext0 theorem;}
{\s18\ql\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext0 bitmapCenter;}
{\s20\qc\sb240\sa240\b\f0\fs36 \sbasedon0\snext21 Title;}
{\s21\qc\sa120\f0\fs24 \sbasedon0\snext0 author;}
{\s22\ql\tqc\tx4536\tqr\tx9072\f0\fs20 \sbasedon0\snext22 footer;}
{\s23\ql\tqc\tx4536\tqr\tx9072\f0\fs20 \sbasedon0\snext23 header;}
{\s30\ql\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext0 caption;}
{\s31\qc\sb120\sa0\keep\widctlpar\f0\fs20 \sbasedon0\snext0 Figure;}
{\s32\qc\sb120\sa0\keep\widctlpar\f0\fs20 \sbasedon0\snext32 Table;}
{\s33\qc\sb120\sa0\keep\widctlpar\f0\fs20 \sbasedon0\snext33 Tabular;}
{\s34\qc\sb120\sa0\keep\widctlpar\f0\fs20 \sbasedon0\snext34 Tabbing;}
{\s35\qj\li1024\ri1024\fi340\widctlpar\f0\fs20 \sbasedon0\snext35 Quote;}
{\s38\ql\widctlpar\f3\fs24 \snext38 verbatim;}
{\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs20 \sbasedon0\snext46 List;}
{\s47\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs20 \sbasedon0\snext47 List 1;}
{\s50\qc\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext0 latex picture;}
{\s51\qc\sb120\sa120\keep\widctlpar\f0 \sbasedon0\snext0 subfigure;}
{\s61\ql\sb240\sa120\keepn\f0\b\fs32 \sbasedon0\snext62 bibheading;}
{\s62\ql\fi-567\li567\sb0\sa0\f0\fs20 \sbasedon0\snext62 bibitem;}
{\s64\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs20 \sbasedon0\snext64 endnotes;}
{\s65\ql\fi-113\li397\lin397\f0\fs24 \sbasedon0\snext65 footnote text;}
{\s66\qj\fi-170\li454\lin454\f0\fs24 \sbasedon0\snext66 endnote text;}
{\cs62\super \additive\sbasedon10 footnote reference;}
{\cs63\super \additive\sbasedon10 endnote reference;}
{\s67\ql\sb60\sa60\keepn\f0\fs24 \sbasedon0\snext67 acronym;}
{\s70\qc\sa120\b\f0\fs24 \sbasedon0\snext71 abstract title;}
{\s71\qj\li1024\ri1024\fi340\widctlpar\f0\fs24 \sbasedon0\snext0 abstract;}
{\s80\ql\sb240\sa120\keepn\f0\b\fs20 \sbasedon0\snext0 contents_heading;}
{\s81\ql\li425\tqr\tldot\tx8222\sb240\sa60\keepn\f0\fs24\b \sbasedon0\snext82 toc 1;}
{\s82\ql\li512\tqr\tldot\tx8222\sb60\sa60\keepn\f0\fs24 \sbasedon0\snext83 toc 2;}
{\s83\ql\li1024\tqr\tldot\tx8222\sb60\sa60\keepn\f0\fs24 \sbasedon0\snext84 toc 3;}
{\s84\ql\li1536\tqr\tldot\tx8222\sb60\sa60\keepn\f0\fs24 \sbasedon0\snext85 toc 4;}
{\s85\ql\li2048\tqr\tldot\tx8222\sb60\sa60\keepn\f0\fs24 \sbasedon0\snext86 toc 5;}
{\s86\ql\li2560\tqr\tldot\tx8222\sb60\sa60\keepn\f0\fs24 \sbasedon0\snext86 toc 6;}
}
{\info
{\title Original file was methods.tex}
{\doccomm Created using latex2rtf 2.3.16 r1254 (released May 12 2017) on Fri Oct  2 17:20:07 2020
}
}
{\footer\pard\plain\f0\fs24\qc\chpgn\par}
\paperw12280\paperh15900\margl1445\margr1445\margt1445\margb1445\pgnstart0\widowctrl\qj\ftnbj\f0\aftnnar
{\pard\plain\s3\ql\sb240\sa120\keepn\f0\b\fs32\sl240\slmult1 \sb240 \fi0 Supplementary Methods\par
\pard\plain\s4\ql\sb240\sa120\keepn\f0\b\fs32\sl240\slmult1 \sb200 \fi0 Bayesian models of IFN-I resistance of HIV-1 plasma isolates from longitudinally sampled participants\par
\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb80 \fi0 To create a simple model of the temporal dynamics of type I interferon (IFN-I) resistance, IFN{{2}}{} and IFN{{}}{} IC{{\field{\*\fldinst{ EQ \\s\\do6({\fs20 50})}}{\fldrslt }}
}{} values were each modeled using a Bayesian change point hierarchical model. The model is based on a segmented regression of the log IC{{\field{\*\fldinst{ EQ \\s\\do6({\fs20 50})}}{\fldrslt }}
}{} making the following simplifying assumptions: {\par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \bullet\tab
Each participant has a level of resistance at the acute infection stage drawn from separate population-level distributions for typical, non- or fast progressors. \par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \bullet\tab
Each participant has a drop (or rise) in IFN-I resistance from acute levels drawn from separate population-level distributions for typical, non- or fast progressors. \par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \bullet\tab
Each participant has a time to nadir drawn from separate population-level distributions for typical, non- or fast progressors. \par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \bullet\tab
Resistance changes linearly from onset of symptoms to time of nadir. \par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \bullet\tab
The nadir of IFN-I resistance represents a changepoint in the data. Following this point, changes in IFN-I resistance are modeled as a linear function of CD4+ T cell count changes away from the count found at nadir. \par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \bullet\tab
Where data is not present, CD4+ T cell counts are assumed to be linearly interpolated between adjacent observations. \par
}\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb80 \fi0 The log IC{{\field{\*\fldinst{ EQ \\s\\do6({\fs20 50})}}{\fldrslt }}
}{} observation from each viral isolate {{\i i}} was modeled as a normal distribution {{\field{\*\fldinst{ EQ {{\i I}{\i C}50}\\s\\do6({\fs20 {\i i}}){\f5\u8764*}{{\i N}{\i o}{\i r}{\i m}{\i a}{\i l}}({\u956*}\\s\\do6({\fs20 {\i i}})\\,{\u963*})}}{\fldrslt }}
} with mean {{\field{\*\fldinst{ EQ {\u956*}\\s\\do6({\fs20 {\i i}})}}{\fldrslt }}
} where: {\par
\pard\plain\s18\ql\sb120\sa120\keep\widctlpar\f0\tqc\tx3450\tqr\tx6900\sl240\slmult1 \sb20 \fi0 \tab
\par
}\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 where the parameters {{\field{\*\fldinst{ EQ {\u945*}\\s\\do6({\fs20 {\i j}})}}{\fldrslt }}
} represent the level of IFN-I resistance at symptom onset, {{\field{\*\fldinst{ EQ {\u948*}\\s\\do6({\fs20 {\i j}})}}{\fldrslt }}
} represents the change from symptom onset to nadir and {{\field{\*\fldinst{ EQ {\i s}\\s\\do6({\fs20 {\i j}})}}{\fldrslt }}
} represents the time of nadir in person {{\i j}}. Study participant data is represented by {{\field{\*\fldinst{ EQ {{\i t}{\i i}{\i m}{\i e}}\\s\\do6({\fs20 {\i i}})}}{\fldrslt }}
} corresponding to the time since onset of symptoms and {{\field{\*\fldinst{ EQ {{\i p}{\i e}{\i r}{\i s}{\i o}{\i n}}\\s\\do6({\fs20 {\i i}})}}{\fldrslt }}
} recording the participant from which isolate {{\i i}} was collected, {{\field{\*\fldinst{ EQ {{\i C}{\i D}4}\\s\\do6({\fs20 {\i j}\\,{\i k}})}}{\fldrslt }}
} containing the estimated CD4+ T cell count for person {{\i j}} at time {{\i k}} and {{\field{\*\fldinst{ EQ {{\i p}{\i r}{\i o}{\i g}{\i r}{\i e}{\i s}{\i s}{\i i}{\i o}{\i n}}\\s\\do6({\fs20 {\i j}})}}{\fldrslt }}
} is the disease progression type (fast/non/typical) for participant {{\i j}}. The hierarchical probabilities for these parameters were: {\par
\pard\plain\s18\ql\sb120\sa120\keep\widctlpar\f0\tqc\tx3450\tqr\tx6900\sl240\slmult1 \sb20 \fi0 \tab
\par
}\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 where {{\i j}} indicates each participant and {{{\i N}{\i e}{\i g}{\i a}{\i t}{\i i}{\i v}{\i e}{\i B}{\i i}{\i n}{\i o}{\i m}{\i i}{\i a}{\i l}({\i x},{\i y})}} represents a negative binomial distribution parameterized such that the expected value is {{\i x}} and the variance is {{\field{\*\fldinst{ EQ {\i x}+ \\F({\i x}\\s\\up6({\fs20 2}),{\i y})}}{\fldrslt }}
}. All hyperparameters were given prior probabilities of {{\field{\*\fldinst{ EQ {\u920*}\\s\\do6({\fs20 {\i x}}){\f5\u8764*}{{\i N}{\i o}{\i r}{\i m}{\i a}{\i l}(0\\,10)}}}{\fldrslt }}
} for parameters representing the means of a distribution and {{\field{\*\fldinst{ EQ {\u964*}\\s\\do6({\fs20 {\i x}}){\f5\u8764*}{{\i G}{\i a}{\i m}{\i m}{\i a}}(1\\,0.1)}}{\fldrslt }}
} for parameters representing standard deviations other than {{\field{\*\fldinst{ EQ {\u920*}\\s\\do6({\fs20 {\u945*}\\,{{\i t}{\i y}{\i p}{\i i}{\i c}{\i a}{\i l}}})}}{\fldrslt }}
} and {{\field{\*\fldinst{ EQ {\u920*}\\s\\do6({\fs20 {\i s}\\,{{\i t}{\i y}{\i p}{\i i}{\i c}{\i a}{\i l}}})}}{\fldrslt }}
} which were given a flat prior and {{\field{\*\fldinst{ EQ {\u964*}\\s\\do6({\fs20 {\i s}}){\f5\u8764*}{{\i C}{\i a}{\i u}{\i c}{\i h}{\i y}}(0\\,10)}}{\fldrslt }}
}.\par
\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 For computational efficiency, the nadir time parameter {{\i s}} was discretized to weekly intervals, assumed to fall within 1 to 150 weeks after symptom onset and marginalized out of the joint probability: \par
\pard\plain\s11\ql\sb120\sa120\keep\widctlpar\f0\tqc\tx3450\sl240\slmult1 \sb20 \fi0 \tab
\par
\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 where {{...}} represents all parameters other than {{\i s}} and {{\field{\*\fldinst{ EQ {\u956*}\\s\\do6({\fs20 {\i i}\\,{\i s}})}}{\fldrslt }}
} is defined the same as {{\field{\*\fldinst{ EQ {\u956*}\\s\\do6({\fs20 {\i i}})}}{\fldrslt }}
}: \par
\pard\plain\s11\ql\sb120\sa120\keep\widctlpar\f0\tqc\tx3450\sl240\slmult1 \sb20 \fi0 \tab
\par
\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 Posterior probabilities were estimated with 50 Markov chain Monte Carlo chains of 5000 iterations each using Stan ({\i 90}{}).\par
\pard\plain\s4\ql\sb240\sa120\keepn\f0\b\fs32\sl240\slmult1 \sb140 \fi0 \scaps0\b0\i Bayesian models of IFN-I resistance of outgrowth and rebound HIV-1 isolates\par
\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb80 \fi0 \scaps0\i To compare the IFN-I resistance of viral isolates derived from plasma samples collected during acute, chronic and rebound infections, as well as from viably frozen PBMCs collected during ART suppression (QVOA), IFN{{2}}{} and IFN{{}}{} IC{{\field{\*\fldinst{ EQ \\s\\do6({\fs20 50})}}{\fldrslt }}
}{} values were modeled using a Bayesian hierarchical model. The model is based on the assumptions that: {\par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \scaps0\i \bullet\tab
Isolates found at acute infection form a base level of IFN-I resistance for a given person. Resistances in virus isolated from chronic, ART suppressed and rebound infection for this person are modelled as changes from this initial level. \par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \scaps0\i \bullet\tab
The mean IC{{\field{\*\fldinst{ EQ \\s\\do6({\fs20 50})}}{\fldrslt }}
}{} level within each person for acute isolates and the change from acute levels for chronic, QVOA and rebound isolates are drawn from a population-level distribution for that type. \par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \scaps0\i \bullet\tab
QVOA isolates are separated into to two populations; a \ldblquote pre\rdblquote  group composed of QVOA viruses isolated from study participants prior to or in the absence of treatment interruption (ATI) and a \ldblquote post\rdblquote  group of QVOA viruses isolated from participants following ATI and reinitiation of ART. \par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \scaps0\i \bullet\tab
In both QVOA populations, the viruses can include some proportion of rebound-like isolates. This mixture is modeled in both pre- and post-treatment so that differences in mixture proportion between the two populations can be assessed. \par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \scaps0\i \bullet\tab
Variation in the potency of INF-I used to experimentally determine IC{{\field{\*\fldinst{ EQ \\s\\do6({\fs20 50})}}{\fldrslt }}
}{} values may shift the inferred resistance for isolates tested in other studies. This effect is modeled as a multiplicative shift in IC{{\field{\*\fldinst{ EQ \\s\\do6({\fs20 50})}}{\fldrslt }}
}{} for all isolates measured outside this study (acute recipient and chronic donor isolates from ref. {\i 50}{}). \par
\pard\plain\s46\ql\fi-283\li283\lin283\sb0\sa120\widctlpar\tql\tx283\f0\fs24\sl240\slmult1 \sb50 \li600\fi-300 \scaps0\i \bullet\tab
Isolates from participants who received exogenous IFN{{2}}{} during treatment interruption may display altered interferon resistance. This effect is modeled as a multiplicative shift in IC{{\field{\*\fldinst{ EQ \\s\\do6({\fs20 50})}}{\fldrslt }}
}{} for all rebound isolates from such participants (participants 004, 030, and 044 from ref. {\i 38}{}). \par
}\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb80 \fi0 \scaps0\i The log IC{{\field{\*\fldinst{ EQ \\s\\do6({\fs20 50})}}{\fldrslt }}
}{} observation from each viral isolate {{\i i}} from acute, chronic and rebound isolates was modeled as a normal distribution: \par
\pard\plain\s11\ql\sb120\sa120\keep\widctlpar\f0\tqc\tx3450\sl240\slmult1 \sb20 \fi0 \scaps0\i \tab
\par
\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 \scaps0\i with the mean resistance for isolate type {{\i j}} from person {{\i k}}: {\par
\pard\plain\s18\ql\sb120\sa120\keep\widctlpar\f0\tqc\tx3450\tqr\tx6900\sl240\slmult1 \sb20 \fi0 \scaps0\i \tab
\par
}\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 \scaps0\i where {{\field{\*\fldinst{ EQ {{\i t}{\i y}{\i p}{\i e}}\\s\\do6({\fs20 {\i i}})}}{\fldrslt }}
} indicates whether isolate {{\i i}} was isolated during acute, chronic, QVOA or rebound infection from participant {{\field{\*\fldinst{ EQ {{\i p}{\i e}{\i r}{\i s}{\i o}{\i n}}\\s\\do6({\fs20 {\i i}})}}{\fldrslt }}
}, {{\field{\*\fldinst{ EQ {{\i b}{\i a}{\i t}{\i c}{\i h}}\\s\\do6({\fs20 {\i k}})}}{\fldrslt }}
} indicates when isolates from person {{\i k}} were tested in another study and {{\field{\*\fldinst{ EQ {{\i I}{\i F}{\i N}}\\s\\do6({\fs20 {\i k}})}}{\fldrslt }}
} indicates when person {{\i k}} was treated with exogenous IFN{{2}}{} prior to and during treatment interruption. Parameters are included for the mean resistance level during acute infection for each person {{\field{\*\fldinst{ EQ {\u945*}\\s\\do6({\fs20 {\i k}})}}{\fldrslt }}
}, standard deviation of isolates of type {{\i j}} within a person {{\field{\*\fldinst{ EQ {\u963*}\\s\\do6({\fs20 {\i j}})}}{\fldrslt }}
}, standard deviation of mean resistance for type {{\i j}} isolates among people {{\field{\*\fldinst{ EQ {\u968*}\\s\\do6({\fs20 {\i j}})}}{\fldrslt }}
}, change from acute levels in isolates of type {{\i j}} in a given participant {{\field{\*\fldinst{ EQ {\u946*}\\s\\do6({\fs20 {\i j}\\,{\i k}})}}{\fldrslt }}
}, the effects of exogenous IFN treatment {{\field{\*\fldinst{ EQ {\u946*}\\s\\do6({\fs20 {\scaps {\i i}{\i f}{\i n}}})}}{\fldrslt }}
} and batch to batch variation in IFN in isolates assayed in previous studies {{\field{\*\fldinst{ EQ {\u946*}\\s\\do6({\fs20 {{\i b}{\i a}{\i t}{\i c}{\i h}}})}}{\fldrslt }}
}. \par
\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 \scaps0\i For QVOA isolates, the IC{{\field{\*\fldinst{ EQ \\s\\do6({\fs20 50})}}{\fldrslt }}
}{} was modeled as a mixture of two populations such that: \par
\pard\plain\s11\ql\sb120\sa120\keep\widctlpar\f0\tqc\tx3450\sl240\slmult1 \sb20 \fi0 \scaps0\i \tab
\par
\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 \scaps0\i where {{\field{\*\fldinst{ EQ {{\i p}{\i r}{\i e}{\i P}{\i o}{\i s}{\i t}}\\s\\do6({\fs20 {\i i}})}}{\fldrslt }}
} indicates whether isolate {{\i i}} was isolated pre- or post-ATI and and {{\field{\*\fldinst{ EQ {\u966*}\\s\\do6({\fs20 }){{\i p}{\i r}{\i e}}}}{\fldrslt }}
} and {{\field{\*\fldinst{ EQ {\u966*}\\s\\do6({\fs20 }){{\i p}{\i o}{\i s}{\i t}}}}{\fldrslt }}
} represent the proportion of rebound-like virus present in pre- and post-ATI QVOA isolates.\par
\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 \scaps0\i The hierarchical parameter priors were modeled as: {\par
\pard\plain\s18\ql\sb120\sa120\keep\widctlpar\f0\tqc\tx3450\tqr\tx6900\sl240\slmult1 \sb20 \fi0 \scaps0\i \tab
\par
}\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 \scaps0\i where {{\i j}} indicates the isolate type (acute, chronic, QVOA, rebound). All {{\field{\*\fldinst{ EQ {\u945*}\\s\\do6({\fs20 {\i k}})}}{\fldrslt }}
}, {{\field{\*\fldinst{ EQ {\u946*}\\s\\do6({\fs20 {\i j}\\,{\i k}})}}{\fldrslt }}
} were given flat priors and {{\field{\*\fldinst{ EQ {\u946*}\\s\\do6({\fs20 {{\scaps {\i i}{\i f}{\i n}}}}){\f5\u8764*}{{\i N}{\i o}{\i r}{\i m}{\i a}{\i l}}(0\\,10)}}{\fldrslt }}
} and {{\field{\*\fldinst{ EQ {\u946*}\\s\\do6({\fs20 {{\i b}{\i a}{\i t}{\i c}{\i h}}}){\f5\u8764*}{{\i N}{\i o}{\i r}{\i m}{\i a}{\i l}}(0\\,10)}}{\fldrslt }}
}.\par
\pard\plain\s0\qj\widctlpar\f0\fs24\sl240\slmult1 \sb20 \fi0 \scaps0\i Posterior probabilities were estimated with 50 Markov chain Monte Carlo chains of 5,000 iterations each using Stan ({\i 90}{}).\par
}}
